Purpose: Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia. We have prospectively evaluated whether intravenous iron can increase the proportion of patients with chemotherapy-related anemia who respond to darbepoetin. Patients and Methods: Between December 2004 and February 2006, 149 patients with lung, gynecologic, breast, and colorectal cancers and 65 12 weeks of planned chemotherapy were enrolled from 33 institutions. Patients were required to have hemoglobin 64 11 g/L and no absolute or functional iron deficiency. All patients received darbepoetin 150 \u3bcg subcutaneously once weekly for 12 weeks and were randomly assigned ...
Abstract Background Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating ...
Study ObjectiveA safe alternative to erythropoiesis-stimulating agents to treat anemia is warranted ...
Study ObjectiveA safe alternative to erythropoiesis-stimulating agents to treat anemia is warranted ...
PURPOSE: Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% to 50% of patients...
PURPOSE: Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% to 50% of patients...
Chemotherapy-induced anemia is often an important problem for cancer patients, and this complication...
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp(TM)) is ...
Abstract: Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia ...
Abstract: Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia ...
Purpose Patients with cancer frequently experience chemotherapy-induced anaemia (CIA) and iron defic...
The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with l...
The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with l...
The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with l...
Background Iron supplementation improves the erythropoiesis-stimulating agents' (ESAs) response in c...
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp™) is an ...
Abstract Background Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating ...
Study ObjectiveA safe alternative to erythropoiesis-stimulating agents to treat anemia is warranted ...
Study ObjectiveA safe alternative to erythropoiesis-stimulating agents to treat anemia is warranted ...
PURPOSE: Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% to 50% of patients...
PURPOSE: Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% to 50% of patients...
Chemotherapy-induced anemia is often an important problem for cancer patients, and this complication...
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp(TM)) is ...
Abstract: Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia ...
Abstract: Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia ...
Purpose Patients with cancer frequently experience chemotherapy-induced anaemia (CIA) and iron defic...
The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with l...
The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with l...
The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with l...
Background Iron supplementation improves the erythropoiesis-stimulating agents' (ESAs) response in c...
Background: Patients receiving chemotherapy often develop anemia. Darbepoetin alfa (Aranesp™) is an ...
Abstract Background Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating ...
Study ObjectiveA safe alternative to erythropoiesis-stimulating agents to treat anemia is warranted ...
Study ObjectiveA safe alternative to erythropoiesis-stimulating agents to treat anemia is warranted ...